Brainsway Dtms denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for brainsway dtms are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Deny BrainsWay Deep TMS as Duplicate Therapy

Humana's duplicate-therapy denial means the insurer has determined that another treatment already authorized or actively in use addresses the same clinical indication. For BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS), this typically arises when a standard TMS device or another neuromodulation modality is on record, leading the plan to conclude a second device-based treatment is redundant.

This denial is routinely appealable because Deep TMS and standard figure-eight coil TMS are distinct cleared devices with different coil geometries, stimulation depths, and FDA-cleared indications. Your appeal should make this clinical and regulatory distinction explicit.

## Federal Appeal Framework

You have layered protections regardless of your plan type:

• ACA §2719 / External Review: Most non-grandfathered plans must offer independent external review. You generally have approximately 4 months (180 days) from the denial notice to request external review. An expedited external review is available when your condition is urgent.
• ERISA §503 (employer-sponsored plans): Entitles you to a full-and-fair review of the denial, access to the criteria used, and a written explanation of the decision.

## Appeal Process and Timeline

1. Request the denial file — obtain the Explanation of Benefits, the denial letter, and Humana's applicable coverage/medical policy by calling the member services number on your card. 2. Internal appeal first — submit within Humana's stated deadline (typically 180 days from denial). Turnaround is generally 30 days for standard, 72 hours for urgent. 3. External review — if the internal appeal is upheld, file for independent external review through the reviewer designated by Humana or your state.

## Documentation to Gather

• Diagnosis confirmation: Chart notes and diagnostic coding establishing the specific condition for which Deep TMS is prescribed.
• Device distinction: A prescriber letter explaining why BrainsWay Deep TMS is not interchangeable with any previously authorized neuromodulation—cite the FDA 510(k) clearance specific to this device and indication.
• Treatment history with dates and outcomes: Records showing what other treatments (including any prior TMS) were tried, when, and their documented results.
• Medical-necessity letter: A detailed letter from the ordering clinician explaining why this specific device is necessary for this patient.

## Criteria-Mapping Structure

Review Humana's published coverage policy for Deep TMS side by side with your chart:

| Policy Requirement | Chart Evidence | |---|---| | Confirmed diagnosis meeting policy criteria | [Enter documented diagnosis from chart] | | Prior treatments tried per step requirements | [List treatments, dates, outcomes] | | Clinical distinction from any active TMS authorization | [Prescriber statement on device/indication differences] | | Ordering provider qualifications | [Specialty and credentials] |

Obtain the exact eligibility criteria from Humana's current medical policy and the FDA-cleared labeling for BrainsWay Deep TMS. Map each requirement to a specific chart fact in your appeal letter.